Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SXHUK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN115429893A ADC4
|
|||||
| Synonyms |
CN115429893A ADC4
Click to Show/Hide
|
|||||
| Organization |
Bio Thera Solutions Ltd
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Hrs9
|
Antibody Info | ||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
CN115429893A ADC1 Payload
|
Payload Info | ||||
| Linker Name |
CB07 linker
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 86.48% | Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
In the MX-1 xenograft model, the ADCs were administered at 2.5 mg/kg (once, IV).
|
||||
| In Vivo Model | MX-1 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 86.48% | Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
In the MX-1 xenograft model, the ADCs were administered at 2.5 mg/kg (once, IV).
|
||||
| In Vivo Model | MX-1 xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 109.48% | Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
In the MX-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | MX-1 xenograft model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 109.48% | Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
In the MX-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | MX-1 xenograft model | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 114.40% | Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
In the Capan-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | Capan-1 xenograft model | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 114.40% | Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
In the Capan-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | Capan-1 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 157.8 ng/mL | Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
MDA-MB-468 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC4 for 120 h.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 233 ng/mL | Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
MX-1 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC4 for 120 h.
|
||||
| In Vitro Model | Breast carcinoma | MX-1 cells | CVCL_4774 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 640 ng/mL | Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
MDA-MB-453 were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC4 for 120 h.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-453 cells | CVCL_0418 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 15000 ng/mL | Negative Trop2 expression (Trop2-) | ||
| Method Description |
HGC27 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC4 for 120 h.
|
||||
| In Vitro Model | Gastric carcinoma | HGC27 cells | CVCL_1279 | ||